Zevra Therapeutics Appoints Global Medical Leader, Adrian

CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics...

Related Keywords

London ,City Of ,United Kingdom ,Ignacio Guerrero Ros ,David Schull ,Neilf Mcfarlane ,Nichol Ochsner ,Zevra Therapeutics Inc ,Compensation Committee Of Zevra Board Directors ,Company Expanded Access Program ,Group Vice ,Erasmus University Medical Center ,Adamas Pharmaceuticals ,Erasmus University Medical School ,Global Medical Affairs At Biomarin Pharmaceuticals Inc ,Exchange Commission ,Clinical Research ,Adrian Quartel ,Chief Medical ,Acer Therapeutics ,Chief Executive Officer ,Chief Medical Officer ,Group Vice President ,Global Medical Affairs ,Biomarin Pharmaceuticals Inc ,Erasmus University Medical ,Pharmaceutical Medicine ,General Medical Council ,Compensation Committee ,Zevra Therapeutics ,Inducement Award Plan ,Nasdaq Rule ,Expanded Access Program ,Note Concerning Forward Looking Statements ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,While Zevra ,Partners Contacts ,Nasdaq Zvra ,